New York, July 22, 2026, 15:10 EDT
- In late afternoon trading, shares climbed 74.6% to $12.36.
- The facility that was terminated represented 2.1 times the preliminary market value estimated on Tuesday.
Shares of Advanced Biomed Inc. NASDAQ:ADVB climbed 74.6% to $12.36 on Wednesday after the company ended a $25 million equity line. A connected share-registration filing was retracted as well. Trading on Nasdaq continued at 15:10 EDT.
The notional facility was more than double the equity base, amounting to 2.1 times the preliminary estimated market value reported on Tuesday.
The calculation is based on 1,652,133 shares reported as of May 29. With shares closing at $7.08 on Tuesday, the estimated value stood at $11.7 million. By Wednesday afternoon, the price increase pushed the value to roughly $20.4 million.
As of 14:55 EDT, trading volume totaled 27.8 million shares, which is 16.8 times the most recent reported share count. The stock hit a peak of $18.07 before falling to trade 31.6% under that level.
Main indexes edged lower. The SPDR S&P Biotech ETF (NYSEARCA:XBI) declined 1.1%, while the iShares Russell 2000 ETF NYSEARCA:IWM dropped 0.8%.
| July 22 indicator | Advanced Biomed | Comparison |
|---|---|---|
| Movement in share price | +74.6% | XBI -1.1%; IWM -0.8% |
| Price and trading range | $12.36 | $7.08 to $18.07 |
| Shares traded | 27.8 million | 16.8 times the reported share count |
| Initial equity valuation | $20.4 million | $11.7 million as of Tuesday |
| Canceled equity facility | $25.0 million | 2.1 times Tuesday’s valuation |
Initial estimates are based on the share count reported on May 29. These figures presume the share count remains unchanged afterward.
This was not a sector-wide rally. Trading volumes were exceptionally high compared to the reported share base.
Advanced Biomed had the option to sell as much as $25 million in stock to Helena Global but was not obligated to utilize the facility. The agreement expired on July 21. According to the filing, no shares were sold in advance. Commitment-fee shares were already issued.
Chief Executive Xiaomin Chen signed an additional withdrawal letter on July 20. According to the company, it had “determined not to proceed with the offering … at this time.” The registration resulted in no securities being sold.
The end of the line eliminates possible future share issuance. It also takes away an optional cash source. Market response on Wednesday indicates traders prioritized the former impact.
The company has shifted its main business area. In April, it acquired Acellent Technologies for 270,000 shares worth $1.08 million. Following the purchase, Advanced Biomed redirected its primary emphasis from life sciences to artificial intelligence.
Advanced Biomed announced it will divest its Taiwan biomedical division for $490,000 as of June 30. The business oversees biomedical research, featuring the A+PerfusC 3D cell-culture platform. The transaction is anticipated to close in the next three months.
The most recent quarterly results do not include the Acellent acquisition. The March quarter saw a loss of $488,942 from continuing operations. As of March 31, cash from continuing operations totaled $2.60 million.
Risks continue to be elevated. The Taiwan sale has yet to close. There is not yet a complete quarter of reported AI activity. Discontinuing the line further limits financing choices. The March-quarter report included a going-concern warning.
Related articles: Biotechnology
